New flexible arrays are lighter, thinner and designed to improve comfort for Optune Gio users ROOT, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug ...
(RTTNews) - Novocure (NVCR) announced the FDA approved new Head Flexible Electrode transducer arrays for use with Optune Gio for the treatment of adult patients with glioblastoma multiforme. Novocure ...
Novocure (NVCR) announced that the FDA approved its new head flexible electrode, or HFE, transducer arrays for use with Optune Gio for the treatment of adult patients with glioblastoma multiforme, or ...
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled in its EF-33 phase 2 pilot trial of Tumor Treating Fields delivered utilizing high ...
ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced receipt of CE Mark for its new polymer-based transducer array, called the flex array, designed for more efficient Tumor ...
What is Optune Gio ® approved to treat? Optune Gio is a wearable, portable, FDA-approved device indicated to treat a type of brain cancer called glioblastoma multiforme (GBM) in adult patients 22 ...
NovoCure announced that the first patient has been enrolled in its EF-33 phase 2 pilot trial of Tumor Treating Fields delivered utilizing high-intensity arrays in patients with recurrent glioblastoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback